ECSP22049654A - Moduladores de canales i?nicos - Google Patents

Moduladores de canales i?nicos

Info

Publication number
ECSP22049654A
ECSP22049654A ECSENADI202249654A ECDI202249654A ECSP22049654A EC SP22049654 A ECSP22049654 A EC SP22049654A EC SENADI202249654 A ECSENADI202249654 A EC SENADI202249654A EC DI202249654 A ECDI202249654 A EC DI202249654A EC SP22049654 A ECSP22049654 A EC SP22049654A
Authority
EC
Ecuador
Prior art keywords
ion channel
abnormal
disease
treating
channel modulators
Prior art date
Application number
ECSENADI202249654A
Other languages
English (en)
Inventor
Carlos Loya
Andrew Griffin
Botella Gabriel Martinez
Kiran Reddy
Brian Marron
Original Assignee
Praxis Prec Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Prec Medicines Inc filed Critical Praxis Prec Medicines Inc
Publication of ECSP22049654A publication Critical patent/ECSP22049654A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transmitters (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Amplifiers (AREA)

Abstract

La presente invenci?n se refiere, en parte, a compuestos y composiciones de heteroarilo fusionado ?tiles para prevenir y/o tratar una enfermedad o afecci?n relacionada con la funci?n an?mala de un canal de ion sodio sensible al voltaje, por ejemplo, corriente de sodio anormal tard?a/constante. Los m?todos para tratar una enfermedad o afecci?n relacionada con la funci?n an?mala de un canal de ion sodio que incluye trastornos neurol?gicos (p. ej., s?ndrome de Dravet, epilepsia), dolor, y trastornos neuromusculares tambi?n se proporcionan en la presente descripci?n.
ECSENADI202249654A 2019-11-26 2022-06-23 Moduladores de canales i?nicos ECSP22049654A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962940500P 2019-11-26 2019-11-26

Publications (1)

Publication Number Publication Date
ECSP22049654A true ECSP22049654A (es) 2022-07-29

Family

ID=76129716

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202249654A ECSP22049654A (es) 2019-11-26 2022-06-23 Moduladores de canales i?nicos

Country Status (16)

Country Link
US (1) US20230034917A1 (es)
EP (1) EP4065124A4 (es)
JP (1) JP2023503343A (es)
KR (1) KR20220119624A (es)
CN (1) CN114980899A (es)
AU (1) AU2020394421A1 (es)
BR (1) BR112022010186A2 (es)
CA (1) CA3162893A1 (es)
CL (1) CL2022001373A1 (es)
CO (1) CO2022008766A2 (es)
EC (1) ECSP22049654A (es)
IL (1) IL293256A (es)
MX (1) MX2022006317A (es)
PE (1) PE20221087A1 (es)
SA (1) SA522432719B1 (es)
WO (1) WO2021108513A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
CN116763791A (zh) 2016-11-28 2023-09-19 普拉克西斯精密药物股份有限公司 化合物以及它们的使用方法
WO2018148745A1 (en) 2017-02-13 2018-08-16 Praxis Precision Medicines , Inc. Compounds and their methods of use
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
CN117756800A (zh) 2018-05-30 2024-03-26 普拉克西斯精密药物股份有限公司 离子通道调节剂
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US20240148709A1 (en) * 2022-11-08 2024-05-09 Aisa Pharma, Inc. Methods of treating eye pain and eye disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010276537B2 (en) * 2009-07-27 2015-04-16 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
KR20230124760A (ko) * 2016-09-02 2023-08-25 사이클리온 테라퓨틱스, 인크. 융합된 비시클릭 sGC 자극제
WO2018098491A1 (en) * 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
CN116763791A (zh) * 2016-11-28 2023-09-19 普拉克西斯精密药物股份有限公司 化合物以及它们的使用方法
WO2018187480A1 (en) * 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
CN117756800A (zh) * 2018-05-30 2024-03-26 普拉克西斯精密药物股份有限公司 离子通道调节剂
US11279700B2 (en) * 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) * 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
WO2021108625A1 (en) * 2019-11-27 2021-06-03 Praxis Precision Medicines, Inc. Formulations of ion channel modulators and methods of preparation and use of ion channel modulators
WO2023211852A1 (en) * 2022-04-26 2023-11-02 Praxis Precision Medicines, Inc. Treatment of neurological disorders

Also Published As

Publication number Publication date
CN114980899A (zh) 2022-08-30
WO2021108513A1 (en) 2021-06-03
AU2020394421A1 (en) 2022-06-09
CO2022008766A2 (es) 2022-07-19
MX2022006317A (es) 2022-06-22
SA522432719B1 (ar) 2023-12-13
CL2022001373A1 (es) 2023-03-10
KR20220119624A (ko) 2022-08-30
US20230034917A1 (en) 2023-02-02
JP2023503343A (ja) 2023-01-27
EP4065124A1 (en) 2022-10-05
CA3162893A1 (en) 2021-06-03
EP4065124A4 (en) 2023-12-06
IL293256A (en) 2022-07-01
BR112022010186A2 (pt) 2022-08-09
PE20221087A1 (es) 2022-07-05

Similar Documents

Publication Publication Date Title
ECSP22049654A (es) Moduladores de canales i?nicos
ECSP22049650A (es) Formulaciones de moduladores de canales i?nicos y m?todos de preparaci?n y uso de moduladores de canales i?nicos
EA202190879A1 (ru) Модуляторы ионных каналов
MX2024000150A (es) Moduladores de los canales ionicos.
CO2022008969A2 (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
PH12020551934A1 (en) Magl inhibitors
CL2020003174S1 (es) Dispositivo para administración de dosis.
BR112015018094A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
UY37113A (es) Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento
BR112015018089A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
CL2017002153A1 (es) Compuestos bicíclicos de sulfonamida cetona
BRPI0408026A (pt) Quinazolinas úteis como moduladores de canais de ìon
WO2018226685A3 (en) METHODS FOR THE SENSITIZATION OF CANCER CELLS TO MEDIATED DESTRUCTION BY T-LYMPHOCYTES BY MOLECULAR PATHWAY MODULATION
BR112015018095A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
MX2021010870A (es) Bloqueadores de canales ionicos cargados y metodos de uso.
MX2022005335A (es) Bloqueadores de canales ionicos cargados y metodos de uso.
CY1124510T1 (el) Υποκατεστημενο βενζοφουρανιο, βενζοπυρρολιο, βενζοθειοφαινιο και δομικα σχετικοι αναστολεις του συμπληρωματος
BR112022000429A2 (pt) Formulações de moduladores do canal de cálcio tipo t e métodos de uso dos mesmos
MX2021010869A (es) Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso.
BR112022006583A2 (pt) Formas cristalinas de estado sólido de um modulador de canal de potássio seletivo
MX2019005384A (es) Sulfonas triciclicas como moduladores del receptor huerfano relacionado con retinoide (ror) gamma.
BR112021021958A2 (pt) Método para recuperação de feixe e dispositivo.
MX9300406A (es) Derivados azabiciclicos procedimientos para su preparacion y composiciones que los contienen.
CL2021003318A1 (es) Compuestos para el tratamiento de trastornos neuromusculares.
CR11117A (es) Formulaciones orales controladas para la liberacion de los compuestos de modulacion del canal del ion y metodos relacionados para evitar arritmia